Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cynata Therapeutics (CYP) receives a notice of allowance for its Cymerus mesenchymal stem from the United States Patent and Trademark Office
  • Cymerus mesenchymal stem cell technology for treating asthma and allergic airways disease
  • The company anticipates the patent will be granted around October 2022, with an expiration date of 31 August, 2038
  • CYP shares is up 1.33 per cent, trading at 38 cents at 1:33 pm AEST

Cynata Therapeutics (CYP) has received a notice of allowance from the United States Patent and Trademark Office.

The notice is for a patent application covering the use of its proprietary Cymerus mesenchymal stem cell technology for treating asthma and allergic airways disease (AAD).

The patent application, entitled “Method for Treating Allergic Airways Disease (AAD)/Asthma,” is wholly owned by Cynata.

In general, notices are sent to applicants when the USPTO intents to issue a patent. This potential new patent will add to the existing IP protection of the Cymerus manufacturing platform and its ability to yield highly consistent mesenchymal stem cells (MSCs) at scale from a single donation to create therapeutic stem cell products.

CEO Ross Macdonald said Cynata is delighted investigations around the utility of Cynata’s proprietary MSCs in lung disease has resulted in another patent.

“This new milestone builds on our portfolio of wholly-Cynata owned patents and patent applications, providing further protection over our proprietary Cymerus technology to 2038 and beyond, particularly in the field of diseases of the lungs,” Dr Macdonald said.    

“The ability of the Cymerus platform to enable the production of consistent, high-quality mesenchymal stem cells at scale is a major competitive advantage and key to the ongoing development of off-the-shelf therapeutic stem cell products to target a range of devastating diseases worldwide”.

Cynata said it anticipates the patent will be granted in October, and will remain valid until the end of August, 2038.

Cynata Therapeutics was up 1.33 per cent, trading at 38 cents at 1:33 pm AEST.

CYP by the numbers
More From The Market Herald
The Market Herald Video

" Caprice Resources (ASX:CRS) intersects shallow gold at Island Gold Project

Caprice Resources (ASX:CRS) intersects shallow gold mineralisation at its first reverse circulation drilling program at the…

" Orion Minerals (ASX:ORN) raises $1.35m in SPP

Orion Minerals (ASX:ORN) has raised $1.35 million in its share purchase plan (SPP) to advance its…

" Future Metals (ASX:FME) to raise $5.5m for Panton

Future Metals (ASX:FME) has received firm commitments for a heavily oversubscribed $5 million placement.

" Firebird Metals (ASX:FRB) raises $3.5m to accelerate Oakover development

Firebird Metals (ASX:FRB) has received firm commitments to raise $3.5 million via a placement from sophisticated…